We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rentschler Invests EUR 24 Million in Stainless Steel Bioreactor Manufacturing
News

Rentschler Invests EUR 24 Million in Stainless Steel Bioreactor Manufacturing

Rentschler Invests EUR 24 Million in Stainless Steel Bioreactor Manufacturing
News

Rentschler Invests EUR 24 Million in Stainless Steel Bioreactor Manufacturing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rentschler Invests EUR 24 Million in Stainless Steel Bioreactor Manufacturing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rentschler Biotechnologie GmbH has announced the investment of €24m to build a Twin system with two 3,000 L stainless steel bioreactors mainly targeting market supply at the company’s site in Laupheim, Germany.

The Twin system is designed for running two main bioreactors in parallel with one shared downstream processing unit thus providing higher throughput while reducing incremental labor costs involved.

It integrates well into the existing 3,000 L GMP line and will more than double the production capacities for cell culture-derived proteins. The Twin system allows us to run cell culture processes in fed-batch mode with a very high output in a single suite.

“The expansion will strengthen our global competitiveness and increase our market awareness of being a CMO partner of first choice all the way down from early clinical trials up to approval and market supply with a wide range of manufacturing technologies to offer” explains Frank Ternes, Chief Business Officer at Rentschler.

In the last few years, Rentschler has been heavily investing in single-use technology and only recently announced that it will add a new 2,000 L single-use bioreactor. Nevertheless, manufacturing in stainless steel is far from being outdated.

Rentschler is experiencing a high demand for stainless steel bioreactor capacity, mainly for market supply, but also for late clinical phases.

The criteria for bioreactor selection includes the characteristics of the product to be manufactured, the approval phase, the expected volume requirements, the required flexibility, and competitive pricing due to optimal technological fit.

Advertisement